Acurx Pharmaceuticals, Inc. (ACXP) 10-Year Financial Performance & Capital Metrics

ACXP • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Show more

Revenue $0
EBITDA $0 +100.0%
Net Income -$14M +3.3%
EPS (Diluted) -17.59 +23.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -534.03% -119.5%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 34.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM44.21%

EPS CAGR

10Y-

5Y-

3Y-

TTM61.09%

ROCE

10Y Avg-341.68%

5Y Avg-265.32%

3Y Avg-299.99%

Latest-534.03%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	5.93M	4.6M	12.81M	12.09M	14.58M	14.1M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	2.42M	2.4M	10.78M	7.34M	8.53M	8.7M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	3.51M	2.2M	2.03M	4.75M	6.04M	5.4M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-5.93M	-4.6M	-12.81M	-12.09M	-14.58M	-14.1M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	0.22%	-1.79%	0.06%	-0.21%	0.03%
EBITDA+	0	0	-12.81M	-12.09M	-14.58M	0
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-	0.06%	-0.21%	1%
D&A (Non-Cash Add-back)	5.93M	4.6M	0	0	0	14.1M
EBIT	-5.93M	-4.6M	-12.81M	-12.09M	-14.58M	-14.1M
Net Interest Income+	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0
Other Income/Expense	0	0	66.5K	0	0	0
Pretax Income+	-5.93M	-4.6M	-12.75M	-12.09M	-14.58M	-14.1M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-5.93M	-4.6M	-12.75M	-12.09M	-14.58M	-14.1M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	0.22%	-1.77%	0.05%	-0.21%	0.03%
Net Income (Continuing)	-5.93M	-4.6M	-12.75M	-12.09M	-14.58M	-14.1M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-12.00	-9.28	-24.96	-22.36	-23.01	-17.59
EPS Growth %	-	0.23%	-1.69%	0.1%	-0.03%	0.24%
EPS (Basic)	-12.00	-9.28	-24.96	-22.36	-23.01	-17.59
Diluted Shares Outstanding	477.05K	495.8K	510.8K	540.8K	633.6K	851.55K
Basic Shares Outstanding	375.1K	495.8K	510.8K	540.8K	633.6K	851.55K
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.53M	3.22M	13.25M	9.38M	7.71M	3.86M
Cash & Short-Term Investments	2.48M	3.18M	12.96M	9.11M	7.47M	3.71M
Cash Only	2.48M	3.18M	12.96M	9.11M	7.47M	3.71M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	129.16K	51.13K
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0
Total Non-Current Assets+	0	0	0	0	0	0
Property, Plant & Equipment	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0
Total Assets+	2.53M	3.22M	13.25M	9.38M	7.71M	3.86M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	0.27%	3.11%	-0.29%	-0.18%	-0.5%
Total Current Liabilities+	1.71M	472.56K	843.91K	2.06M	3.04M	3.24M
Accounts Payable	0	0	0	0	0	0
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	16.63K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	1.31M	317.07K	508.34K	542.89K	716.31K	537.63K
Current Ratio	1.48x	6.82x	15.71x	4.55x	2.53x	1.19x
Quick Ratio	1.48x	6.82x	15.71x	4.55x	2.53x	1.19x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	49.88K	0	0	0	0
Long-Term Debt	0	49.88K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0
Total Liabilities	1.71M	522.43K	843.91K	2.06M	3.04M	3.24M
Total Debt+	0	66.5K	0	0	0	0
Net Debt	-2.48M	-3.11M	-12.96M	-9.11M	-7.47M	-3.71M
Debt / Equity	-	0.02x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	819.85K	2.7M	12.41M	7.32M	4.67M	615.12K
Equity Growth %	-	2.3%	3.59%	-0.41%	-0.36%	-0.87%
Book Value per Share	1.72	5.45	24.30	13.53	7.37	0.72
Total Shareholders' Equity	819.85K	2.7M	12.41M	7.32M	4.67M	615.12K
Common Stock	10.02M	16.5M	10.22K	11.63K	14.47K	17.03K
Retained Earnings	-9.2M	-13.8M	-26.55M	-38.64M	-53.22M	-67.32M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-9.2M	-13.8M	-26.55M	-38.64M	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.99M	-3.35M	-5.01M	-7.54M	-9.8M	-10.38M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	0.16%	-0.5%	-0.5%	-0.3%	-0.06%
Net Income	-5.93M	-4.6M	-12.75M	-12.09M	-14.58M	-14.1M
Depreciation & Amortization	0	0	0	0	0	0
Stock-Based Compensation	900.43K	1.27M	6.74M	3.3M	3.77M	3.44M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	0	781.7K	850.26K	0	0	0
Working Capital Changes	1.05M	-801.17K	141.28K	1.25M	1.01M	284.09K
Change in Receivables	0	0	0	0	-129.16K	78.03K
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0
Cash from Investing+	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	4.46M	4.04M	14.8M	3.7M	8.16M	6.62M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	0	13	2.22M	210.2K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-3.99M	-3.35M	-5.01M	-7.54M	-9.8M	-10.38M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	0.16%	-0.5%	-0.5%	-0.3%	-0.06%
FCF per Share	-8.35	-6.76	-9.82	-13.95	-15.47	-12.19
FCF Conversion (FCF/Net Income)	0.67x	0.73x	0.39x	0.62x	0.67x	0.74x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-723.45%	-261.26%	-168.71%	-122.61%	-243.33%	-534.03%
Debt / Equity	-	0.02x	-	-	-	-
FCF Conversion	0.67x	0.73x	0.39x	0.62x	0.67x	0.74x

Frequently Asked Questions

Growth & Financials

Acurx Pharmaceuticals, Inc. (ACXP) grew revenue by 0.0% over the past year. Growth has been modest.

Acurx Pharmaceuticals, Inc. (ACXP) reported a net loss of $9.2M for fiscal year 2024.

Dividend & Returns

Acurx Pharmaceuticals, Inc. (ACXP) has a return on equity (ROE) of -534.0%. Negative ROE indicates the company is unprofitable.

Acurx Pharmaceuticals, Inc. (ACXP) had negative free cash flow of $7.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener